(VIANEWS) – Catalyst Pharmaceuticals (CPRX), Meta Platforms (META), Hexcel Corporation (HXL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Catalyst Pharmaceuticals (CPRX)
16.7% sales growth and 13.85% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.85%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.2%, now sitting on 434.48M for the twelve trailing months.
Moving Average
Catalyst Pharmaceuticals’s value is way below its 50-day moving average of $17.00 and below its 200-day moving average of $15.57.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 203.4% and a drop 9.7% for the next.
Volume
Today’s last reported volume for Catalyst Pharmaceuticals is 817840 which is 36.47% below its average volume of 1287390.
2. Meta Platforms (META)
14.8% sales growth and 35.37% return on equity
Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California
Earnings Per Share
As for profitability, Meta Platforms has a trailing twelve months EPS of $14.86.
PE Ratio
Meta Platforms has a trailing twelve months price to earnings ratio of 34.45. Meaning, the purchaser of the share is investing $34.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.37%.
Volume
Today’s last reported volume for Meta Platforms is 10799200 which is 38.45% below its average volume of 17545500.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.1%, now sitting on 149.78B for the twelve trailing months.
Previous days news about Meta Platforms(META)
- According to Zacks on Tuesday, 27 August, "OpenAI and Microsoft’s ((MSFT Quick QuoteMSFT – Free Report) ) late 2022 launch of their wildly popular large language model (LLM) ChatGPT sparked a flurry of investment in the AI realm from big-cap tech companies like Meta Platforms ((META Quick QuoteMETA – Free Report) ), Alphabet ((GOOGL Quick QuoteGOOGL – Free Report) ), and Amazon ((AMZN Quick QuoteAMZN – Free Report) ). "
- Meta platforms (meta) stock moves 0.28%: what you should know. According to Zacks on Thursday, 29 August, "The investment community will be paying close attention to the earnings performance of Meta Platforms in its upcoming release. ", "Valuation is also important, so investors should note that Meta Platforms has a Forward P/E ratio of 24.26 right now. "
3. Hexcel Corporation (HXL)
10% sales growth and 6.61% return on equity
Hexcel Corporation, together with its subsidiaries, develops, manufactures, and markets structural materials for use in commercial aerospace, space and defense, and industrial markets. It operates through two segments, Composite Materials and Engineered Products. The Composite Materials segment manufactures and markets carbon fibers, fabrics and specialty reinforcements, prepregs and other fiber-reinforced matrix materials, structural adhesives, honeycomb, molding compounds, tooling materials, polyurethane systems, and laminates that are used in military and commercial aircraft, wind turbine blades, recreational products, and other industrial applications, as well as in automotive, marine, and trains. The Engineered Products segment manufactures and markets aircraft structures and finished aircraft components, including wing to body fairings, wing panels, flight deck panels, door liners, rotorcraft blades, spars, and tip caps; and aircraft structural sub-components and semi-finished components used in rotorcraft blades, engine nacelles, and aircraft surfaces, such as flaps, wings, elevators, and fairings. The company sells its products directly through its managers, product managers, and sales personnel, as well as through independent distributors and manufacturer representatives in the Americas, Europe, the Asia Pacific, India, and Africa. Hexcel Corporation was founded in 1946 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Hexcel Corporation has a trailing twelve months EPS of $1.27.
PE Ratio
Hexcel Corporation has a trailing twelve months price to earnings ratio of 50.37. Meaning, the purchaser of the share is investing $50.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.61%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Aug 2, 2024, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 0.94%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 26.3% and 37.2%, respectively.
4. STAAR Surgical Company (STAA)
5.4% sales growth and 4.36% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.33.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 114.88. Meaning, the purchaser of the share is investing $114.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.36%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.3%, now sitting on 332.94M for the twelve trailing months.
Yearly Top and Bottom Value
STAAR Surgical Company’s stock is valued at $37.91 at 06:22 EST, way under its 52-week high of $52.68 and way above its 52-week low of $26.66.
Moving Average
STAAR Surgical Company’s value is below its 50-day moving average of $41.50 and above its 200-day moving average of $37.82.
